ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

NCT03494504 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

318

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Conjunctivitis

Interventions

DRUG: Reproxalap Ophthalmic Solution (0.25%)
DRUG: Reproxalap Ophthalmic Solution (0.5%)
DRUG: Vehicle Ophthalmic Solution

Sponsor

Aldeyra Therapeutics, Inc.